论文部分内容阅读
2型糖尿病是一种渐进性疾病,因此需渐进性的治疗方法。美国礼来公司研究实验室洲际医学事务主管James Anderson博士近日对糖尿病不同发展阶段的药物研发新动向进行了阐述。模仿肠降血糖素药Anderson博士首先对新药Exenatide(人工合成的exendin-4,被称为“针对2型糖尿病治疗的新方法”)进行了介绍;2型糖尿病患者在被确诊时,其β细胞功能(通过适当的胰岛素分泌应答血糖变化的能力)可能已降低50%;即使应用二甲双胍、磺酰脲类药物或胰岛素,患者的β细胞功能仍以每年4%的速度继续恶化。
Type 2 diabetes is a progressive disease that requires progressive treatment. Dr. James Anderson, director of intercontinental medical affairs at the research laboratory of Eli Lilly and Company in the United States, recently described the new trend of drug development in different stages of diabetes. Analogue of the incretin drug Dr. Anderson first introduced the new drug Exenatide (a synthetic exendin-4 called “a new method for the treatment of type 2 diabetes”); patients with type 2 diabetes were diagnosed β-cell function (the ability to respond to glycemic changes by proper insulin secretion) may have been reduced by 50%; even with metformin, sulfonylureas, or insulin, patients’ β-cell function continues to deteriorate at 4% per year.